By Lauran Neergaard

New research suggests that Pfizer’s COVID-19 vaccine can protect against a mutation found in two easier-to-spread variants of the coronavirus that erupted in Britain and South Africa.

Those variants are causing global concern. They carry multiple mutations but share one in common that's believed to be the reason they are more contagious. Called N501Y, it is a slight alteration on one spot of the spike protein that coats the virus.

Most of the vaccines being rolled out around the world train the body to recognize that spike protein and fight it. Pfizer teamed with researchers from the University of Texas Medical Branch in Galveston for laboratory tests to see if the mutation affected its vaccine's ability to do so.

They used blood samples from 20 people who received the vaccine, made by Pfizer and its German partner BioNTech, during a large study of the shots. Antibodies from those vaccine recipients successfully fended off the virus in lab dishes, according to the study posted late Thursday on an online site for researchers.

The study is preliminary and has not yet been reviewed by experts, a key step for medical research.

But “it was a very reassuring finding that at least this mutation, which was one of the ones people are most concerned about, does not seem to be a problem” for the vaccine, said Pfizer chief scientific officer Dr. Philip Dormitzer.

A similar vaccine by Moderna is being rolled out in the U.S. and Europe, and on Friday was cleared in Britain. Moderna is doing similar testing to tell if its shot also works against the variants, as are makers of other types of COVID-19 vaccines.

But Dr. Anthony Fauci, the top U.S. infectious disease expert, recently told The Associated Press that vaccines are designed to recognize multiple parts of the spike protein, making it unlikely a single mutation could be enough to block them. Still, testing is needed to be sure.

Viruses constantly undergo minor changes as they spread from person to person. Scientists have used these slight modifications to track how the coronavirus has moved around the globe since it was first detected in China about a year ago.

British scientists have said the variant found in the U.K. – which has become the dominant type in parts of England -- still seemed to be susceptible to vaccines. That mutant has now been found in the U.S. and numerous other countries.

But the variant first discovered in South Africa has an additional mutation that has scientists on edge, one named E484K.

The Pfizer study found that the vaccine appeared to work against 15 additional possible virus mutations, but E484K wasn’t among those tested. Dormitzer said it is next on the list.

If the virus eventually mutates enough that the vaccine needs adjusting – much like flu shots are adjusted most years – that tweaking the recipe wouldn’t be difficult for his company's shot and similar ones. Both the Pfizer-BioNTech and Moderna vaccines are made with a piece of the virus genetic code, simple to switch, although it’s not clear what kind of additional testing regulators would require to make such a change.

Dormitzer said this was only the beginning “of ongoing monitoring of virus changes to see if any of them might impact on vaccine coverage.”

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Moderna Seeks FDA Authorization of Omicron-Specific Booster
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
JWST's Gregory Robinson Expects to See 'Universe Different' in New Images
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
Human Evolution Speeding Up; Advancements in Genetic Engineering
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Editing the Human Genome
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
Why Humans are Evolving Faster Than Ever Before
Professor Laurence Hurst, Director of The Milner Centre for Evolution, joins Cheddar Reveals to discuss the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up?
'Designed to Disappear': Loliware's Seaweed-Based Straws Offer Eco-Friendly Alternative
It can be tough to make sustainable choices, and even harder when sustainable materials don't hold up. Loliware has a solution to the plastic straw problem: its seaweed-based straws are stronger than paper alternatives and once used, can be composted and return to the earth or sea without causing harm. Sea Briganti, CEO of Loliware, joins Closing Bell to discuss the tech behind the straws, new product launches, and more.
Anja Health Raises $4.5 Million to Offer Parents Technology to Freeze Umbilical Cord's Stem Cells for Future Disease Treatment
Umbilical cord blood banking platform Anja Health raised $4.5 million dollars in a seed round led by Seven Seven Six, a venture capital firm founded by Reddit co-founder Alexis Ohanian. Anja Health offers a personalized, doctor-backed cord blood bank, which lets new parents freeze stem cells from their child's umbilical cord so they can be used to treat diseases in the future. It's a process Anja has called 'Hollywood's best-kept secret,' as celebrities like Kylie Jenner, Serena Williams, and more have all banked their umbilical cord blood. Kathryn Cross, the founder of Anja Health, joins Cheddar News' Closing Bell to discuss.
Calls Grow for Social Media to Flag Threats in Wake of School Shooting
After learning that the suspect in the Uvalde school shooting posted about his intentions on Facebook, activists are urging social networks to make changes. Lena Derhally, a licensed psychotherapist and author of "The Facebook Narcissist," joined Cheddar News to discuss the role social media plays in school shootings. "They're not really invested in taking down hateful content," she said about social platforms."In regards to the shooting, it was 15 minutes before that actual threat. It would be pretty hard for a social media company to trace that threat that quickly. But what they can do better is take down threats and hateful content much faster and more than they're doing now."
Load More